Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)
AACR21: Sanofi rolls out new data for early-stage 'non-alpha' IL-2. Early feedback? Interesting, but mostly meh
When Paul Hudson over at Sanofi inked a $2.5 billion buyout of cancer player Synthorx in late 2019, one of the centerpieces of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.